WO2002004514A3 - Compositions et procedes pour le traitement et le diagnostic du cancer du poumon - Google Patents

Compositions et procedes pour le traitement et le diagnostic du cancer du poumon Download PDF

Info

Publication number
WO2002004514A3
WO2002004514A3 PCT/US2001/022058 US0122058W WO0204514A3 WO 2002004514 A3 WO2002004514 A3 WO 2002004514A3 US 0122058 W US0122058 W US 0122058W WO 0204514 A3 WO0204514 A3 WO 0204514A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
diagnosis
lung cancer
therapy
polypeptides
Prior art date
Application number
PCT/US2001/022058
Other languages
English (en)
Other versions
WO2002004514A2 (fr
WO2002004514A8 (fr
Inventor
Tongtong Wang
Yoshihiro Watanabe
Robert A Henderson
Jeffrey C Johnson
Marc W Retter
Margarita Durham
Darrick Carter
Gary Richard Fanger
Thomas S Vedvick
Chaitanya S Bangur
Andria Mcnabb
Aijun Wang
Neil Fanger
Ann Switzer
Patricia D Mcneill
Jonathan D Clapper
Original Assignee
Corixa Corp
Tongtong Wang
Yoshihiro Watanabe
Robert A Henderson
Jeffrey C Johnson
Marc W Retter
Margarita Durham
Darrick Carter
Gary Richard Fanger
Thomas S Vedvick
Chaitanya S Bangur
Andria Mcnabb
Aijun Wang
Neil Fanger
Ann Switzer
Patricia D Mcneill
Jonathan D Clapper
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/614,124 external-priority patent/US6630574B1/en
Priority claimed from US09/651,563 external-priority patent/US6914132B1/en
Priority claimed from US09/658,824 external-priority patent/US6746846B1/en
Priority claimed from US09/671,325 external-priority patent/US6667154B1/en
Priority claimed from US09/702,705 external-priority patent/US6504010B1/en
Priority claimed from US09/736,457 external-priority patent/US6509448B2/en
Priority claimed from US09/849,626 external-priority patent/US20020197669A1/en
Priority to AU2002218770A priority Critical patent/AU2002218770A1/en
Priority to JP2002509377A priority patent/JP2004512824A/ja
Application filed by Corixa Corp, Tongtong Wang, Yoshihiro Watanabe, Robert A Henderson, Jeffrey C Johnson, Marc W Retter, Margarita Durham, Darrick Carter, Gary Richard Fanger, Thomas S Vedvick, Chaitanya S Bangur, Andria Mcnabb, Aijun Wang, Neil Fanger, Ann Switzer, Patricia D Mcneill, Jonathan D Clapper filed Critical Corixa Corp
Priority to EP01984164A priority patent/EP1343886A2/fr
Priority to CA002415544A priority patent/CA2415544A1/fr
Publication of WO2002004514A2 publication Critical patent/WO2002004514A2/fr
Publication of WO2002004514A8 publication Critical patent/WO2002004514A8/fr
Publication of WO2002004514A3 publication Critical patent/WO2002004514A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne des compositions et des procédés pour le traitement et le diagnostic du cancer, en particulier du cancer du poumon. Les compositions typiques comprennent un ou plusieurs polypeptides de tumeur pulmonaire, des parties immunogènes de ceux-ci, des polynucléotides qui codent pour ces polypeptides, une cellules présentatrice d'antigène qui exprime ces polypeptides, et des lymphocytes T spécifiques de cellules exprimant ces polypeptides. Les compositions décrites sont utiles, par exemple, dans le diagnostic, la prévention et/ou le traitement de maladies, en particulier le cancer du poumon.
PCT/US2001/022058 2000-07-11 2001-07-10 Compositions et procedes pour le traitement et le diagnostic du cancer du poumon WO2002004514A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002415544A CA2415544A1 (fr) 2000-07-11 2001-07-10 Compositions et procedes pour le traitement et le diagnostic du cancer du poumon
EP01984164A EP1343886A2 (fr) 2000-07-11 2001-07-10 Compositions et procedes pour le traitement et le diagnostic du cancer du poumon
AU2002218770A AU2002218770A1 (en) 2000-07-11 2001-07-10 Compositions and methods for the therapy and diagnosis of lung cancer
JP2002509377A JP2004512824A (ja) 2000-07-11 2001-07-10 肺癌の治療および診断のための組成物および方法

Applications Claiming Priority (16)

Application Number Priority Date Filing Date Title
US09/614,124 2000-07-11
US09/614,124 US6630574B1 (en) 1999-06-30 2000-07-11 Compositions and methods for the therapy and diagnosis of lung cancer
US09/651,563 US6914132B1 (en) 1999-06-30 2000-08-29 Compositions and methods for the therapy and diagnosis of lung cancer
US09/651,563 2000-08-29
US09/658,824 2000-09-08
US09/658,824 US6746846B1 (en) 1999-06-30 2000-09-08 Methods for diagnosing lung cancer
US09/671,325 2000-09-26
US09/671,325 US6667154B1 (en) 1999-06-30 2000-09-26 Compositions and methods for the therapy and diagnosis of lung cancer
US67741900A 2000-10-06 2000-10-06
US09/677,419 2000-10-06
US09/702,705 US6504010B1 (en) 1999-06-30 2000-10-30 Compositions and methods for the therapy and diagnosis of lung cancer
US09/702,705 2000-10-30
US09/736,457 2000-12-13
US09/736,457 US6509448B2 (en) 1999-06-30 2000-12-13 Compositions and methods for the therapy and diagnosis of lung cancer
US09/849,626 2001-05-03
US09/849,626 US20020197669A1 (en) 2000-12-13 2001-05-03 Compositions and methods for the therapy and diagnosis of lung cancer

Publications (3)

Publication Number Publication Date
WO2002004514A2 WO2002004514A2 (fr) 2002-01-17
WO2002004514A8 WO2002004514A8 (fr) 2002-12-27
WO2002004514A3 true WO2002004514A3 (fr) 2003-06-19

Family

ID=27575493

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/022058 WO2002004514A2 (fr) 2000-07-11 2001-07-10 Compositions et procedes pour le traitement et le diagnostic du cancer du poumon

Country Status (6)

Country Link
EP (1) EP1343886A2 (fr)
JP (1) JP2004512824A (fr)
AR (1) AR031250A1 (fr)
AU (1) AU2002218770A1 (fr)
CA (1) CA2415544A1 (fr)
WO (1) WO2002004514A2 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030170255A1 (en) * 1999-06-30 2003-09-11 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US20030211510A1 (en) 1999-06-30 2003-11-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6893818B1 (en) 1999-10-28 2005-05-17 Agensys, Inc. Gene upregulated in cancers of the prostate
EP1250426A2 (fr) * 1999-12-01 2002-10-23 Genentech Inc. Polypeptides transmembranaires et secretes et les acides nucleiques codant ceux-ci
US20030166300A1 (en) * 2000-08-30 2003-09-04 Tang Y. Tom Growth-related inflammatory and immune response protein
ZA200204907B (en) 2001-06-26 2003-03-03 Univ Nat Taiwan Collapsin Response Mediator Protein-1.
EP1543018A4 (fr) * 2002-08-14 2006-10-25 Lg Life Sciences Ltd Familles de genes associees au cancer du foie
JP2006519582A (ja) * 2002-09-26 2006-08-31 ジェネンテック・インコーポレーテッド 乾癬の治療のための新規組成物と方法
TW200413725A (en) * 2002-09-30 2004-08-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancers
US7449291B1 (en) * 2003-01-13 2008-11-11 University Of Washington Methods for identifying subjects susceptible to Charcot-Marie-Tooth neuropathy type 1C
WO2004070058A1 (fr) * 2003-02-03 2004-08-19 Bayer Healthcare Ag Methodes et compositions permettant de prevoir, diagnostiquer, pronostiquer, prevenir et traiter des broncho-pneumopathies chroniques obstructives
CA2520512A1 (fr) * 2003-03-24 2004-10-07 Corixa Corporation Methodes, compositions et trousses pour la detection et pour la surveillance d'un cancer du poumon
ATE528397T1 (de) 2003-08-08 2011-10-15 Perseus Proteomics Inc Bei krebs überexprimiertes gen
EP1668354A2 (fr) * 2003-09-24 2006-06-14 Oncotherapy Science, Inc. Methode de diagnostic du cancer du sein
JP4428995B2 (ja) 2003-12-03 2010-03-10 関東化学株式会社 金属膜のエッチング液組成物
CA2555509A1 (fr) * 2004-01-27 2005-07-27 Compugen Usa, Inc. Nouvelles sequences d'acides amines et de nucleotides, et dosages et methodes d'utilisation connexes pour le diagnostic du cancer du poumon
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
KR101300544B1 (ko) 2004-03-31 2013-09-02 히로유키 아브라타니 항ｒｏｂｏ1항체를 이용하는 암의 진단 및 치료
US8940488B2 (en) 2004-03-31 2015-01-27 Hiroyuki Aburatani Cancer diagnosis and treatment of cancer using anti-robo 1 antibody
EP1915622A2 (fr) * 2005-07-29 2008-04-30 Oncotherapy Science, Inc. Criblage et methode therapeutique anti-nsclc ciblant le complexe cda1-kntc2
WO2008076127A1 (fr) * 2006-12-21 2008-06-26 Intradigm Corporation Compositions inhibitrices de polynucléotide et procédés de traitement du cancer
JP5117765B2 (ja) 2007-05-28 2013-01-16 国立大学法人 東京大学 抗ｒｏｂｏ１抗体を含むｐｅｔ用腫瘍診断剤
PT2186889E (pt) 2007-08-20 2015-06-17 Oncotherapy Science Inc Péptido cdca1 e agente farmacêutico que o compreende
TWI526219B (zh) 2008-06-19 2016-03-21 腫瘤療法 科學股份有限公司 Ｃｄｃａ１抗原決定位胜肽及含此胜肽的疫苗
EP2433964A4 (fr) * 2009-05-22 2013-09-11 Univ Okayama Nat Univ Corp Peptide induisant une réponse immunitaire spécifique contre xage-1b et son utilisation
EP2872532A4 (fr) * 2012-07-10 2016-04-13 Oncotherapy Science Inc Peptides épitopes du cdca1 pour cellules th1 et vaccins les contenant
CN114102955B (zh) * 2020-08-31 2024-05-07 天津科技大学 一种采用常温发泡技术制备发泡聚乳酸的方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999038973A2 (fr) * 1998-01-28 1999-08-05 Corixa Corporation Composes destines au diagnostic et a la therapie du cancer du poumon et procedes d'utilisation associes
WO2000055375A1 (fr) * 1999-03-17 2000-09-21 Alphagene, Inc. Proteines secretees et polynucleotides les codant

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10139800A (ja) * 1996-11-15 1998-05-26 Santen Pharmaceut Co Ltd シェーグレン症候群治療剤
MXPA02000192A (es) * 1999-06-30 2004-08-12 Corixa Corp Composiciones y metodos para la terapia y diagnostico de cancer de pulmon.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999038973A2 (fr) * 1998-01-28 1999-08-05 Corixa Corporation Composes destines au diagnostic et a la therapie du cancer du poumon et procedes d'utilisation associes
WO2000055375A1 (fr) * 1999-03-17 2000-09-21 Alphagene, Inc. Proteines secretees et polynucleotides les codant

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
CHEN S-L ET AL: "Isolation and characterizaton of a novel gene expressed in multiple cancers", ONCOGENE, BASINGSTOKE, HANTS, GB, vol. 12, no. 4, 15 February 1996 (1996-02-15), pages 741 - 751, XP002106655, ISSN: 0950-9232 *
DATABASE EMBL [online] 1 July 1997 (1997-07-01), "ab23f06.r1 Stratagene lung (#937210) Homo sapiens cDNA clone", XP002199797, Database accession no. AA488696 *
DATABASE EMBL [online] 5 March 1995 (1995-03-05), XP002199799, Database accession no. T63732.1 *
DATABASE EMBL [online] 7 June 2000 (2000-06-07), "Homo sapiens cDNA", XP002199798, Database accession no. AW950090 *
GÜRE ET AL: "Human lung cancer antigens recognized by autologous antibodies: definition of a novel cDNA derived from the tumor suppressor gene locus on chromosome 3p21.3", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 58, 1 March 1998 (1998-03-01), pages 1034 - 1041, XP002103188, ISSN: 0008-5472 *
HILLIER L ET AL: "GENERATION AND ANALYSIS OF 280,000 HUMAN EXPRESSED SEQUENCE TAGS", GENOME RESEARCH, COLD SPRING HARBOR LABORATORY PRESS, US, vol. 6, 1996, pages 807 - 828, XP002942261, ISSN: 1088-9051 *
ZANGEMEISTER-WITTKE U ET AL: "REVIEW NOVEL APPROACHES TO THE TREATMENT OF SMALL-CELL LUNG CANCER", CMLS CELLULAR AND MOLECULAR LIFE SCIENCES, BIRKHAUSER VERLAG, BASEL, CH, vol. 55, no. 12, September 1999 (1999-09-01), pages 1585 - 1598, XP000960960, ISSN: 1420-682X *

Also Published As

Publication number Publication date
AU2002218770A1 (en) 2002-01-21
WO2002004514A2 (fr) 2002-01-17
WO2002004514A8 (fr) 2002-12-27
CA2415544A1 (fr) 2002-01-17
EP1343886A2 (fr) 2003-09-17
AR031250A1 (es) 2003-09-17
JP2004512824A (ja) 2004-04-30

Similar Documents

Publication Publication Date Title
WO2001072295A3 (fr) Compositions et methodes pouvant traiter ou diagnostiquer le cancer du poumon
WO2001092581A8 (fr) Compositions et methodes permettant le traitement et le diagnostic du cancer de l'ovaire
WO2002060317A3 (fr) Compositions et methodes pour le traitement et le diagnostic du cancer du pancreas
WO2002004514A3 (fr) Compositions et procedes pour le traitement et le diagnostic du cancer du poumon
WO2002074156A8 (fr) Compositions et procedes de therapie et de diagnostic du cancer du colon
WO2001051633A3 (fr) Compositions et methodes destinees au traitement et au diagnostique du cancer de la prostate
WO2002089747A3 (fr) Compositions et procedes pour la therapie et le diagnostic du cancer de la prostate
WO2001073032A3 (fr) Compositions et methodes de therapie et de diagnostic du cancer de la prostate
WO2004052276A3 (fr) Compositions et procedes pour la therapie et le diagnostic du cancer de la prostate
WO2002092001A3 (fr) Compositions et methodes de traitement et de diagnostic du cancer du poumon
WO2002016413A3 (fr) Vaccins
WO2002074237A8 (fr) Compositions et procedes de therapie et de diagnostic du cancer du rein
WO2002014503A3 (fr) Compositions et methodes de traitement et de diagnostic de cancers associes a her-2/neu
WO2002012328A8 (fr) Compositions et methodes utilisees dans la therapie et le diagnostic du cancer du colon
WO2006031363A3 (fr) Compositions et procedes pour la therapie et le diagnostic du cancer du poumon
WO2003037267A8 (fr) Compositions et methodes de traitement et de diagnostic du cancer des poumons
WO2002058534A8 (fr) Compositions et methodes pour le traitement et le diagnostic du cancer du colon
WO2002078516A3 (fr) Compositions et methodes de traitement et de diagnostic de cancers
WO2001077168A3 (fr) Compositions et procedes permettant de traiter et de diagnostiquer le cancer du poumon
WO2002039885A3 (fr) Compositions et methodes destinees a la therapie et au diagnostic du cancer de l'ovaire
WO2002012280A3 (fr) Compositions et procedes pour le diagnostic et le traitement du cancer du colon
WO2003013431A3 (fr) Compositions et techniques de therapie et de diagnostic du cancer du sein
WO2001090152A3 (fr) Compositions et procedes pour la therapie et le diagnostic du cancer du sein
WO2002000174A3 (fr) Compositions et methodes pour le traitement et le diagnostic du cancer du poumon
WO2003086175A3 (fr) Compositions et procedes destines au traitement et au diagnostic du cancer du poumon

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

AK Designated states

Kind code of ref document: C1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i
WWE Wipo information: entry into national phase

Ref document number: 2415544

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001984164

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001984164

Country of ref document: EP